CHICAGO -- A perioperative regimen of four cycles of chemotherapy before and after surgery extended overall survival (OS) compared with neoadjuvant chemoradiation in patients with locally-advanced, ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca's IMFINZI ® (durvalumab) in combination with ...
For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) leads to improved survival compared with ...
Imfinzi (durvalumab) is an immunotherapy medicine that helps the immune system detect and attack cancer cells. The FDA has approved a combination of Imfinzi and standard chemotherapy medicines – ...
A Peter Mac-led international clinical trial has found a way to personalize treatment for gastroesophageal cancer, identifying patients who could avoid further intensive rounds of chemotherapy while ...
Imfinzi plus FLOT chemotherapy significantly improves overall survival in resectable G/GEJ adenocarcinoma compared to placebo plus FLOT. The MATTERHORN trial showed consistent survival benefits across ...
Imfinzi plus chemotherapy, when given before surgery, improved pathologic complete response rates, regardless of region, in certain patients with gastric or gastroesophageal junction cancers. Adding ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca’s IMFINZI® (durvalumab) added to ...
Please provide your email address to receive an email when new articles are posted on . FLOT protocol conferred longer OS at multiple endpoints compared with CROSS in patients with advanced esophageal ...
CHICAGO -- Adding perioperative durvalumab (Imfinzi) to FLOT chemotherapy significantly improved event-free survival (EFS) compared with FLOT alone in patients with resectable gastric or ...
Overall survival at 3 years was 57.4% and 50.7% in the FLOT and preoperative-chemoradiotherapy groups, respectively, with a median follow-up of 55 months. Jens Hoeppner, MD, from Bielefeld University ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results